TENX SCHEDULE 13G/A: SEC filing

Biotechnology Value Fund L.P. and affiliated entities

Filed with the SEC on · accession 0000921895-26-003191

TENX filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. A report the company filed with the SEC (the US market regulator). The stock moved -8.6% by the first close after the filing.

Summary of the filing

Biotechnology Value Fund L.P. and affiliated entities filed an amended Schedule 13G disclosing beneficial ownership of approximately 9.99% of Tenax Therapeutics' common stock, including shares underlying pre-funded warrants subject to a 9.99% ownership blocker.

Key details

Shares beneficially owned by BVF Partners L.P. (aggregate)$4.2M
Shares beneficially owned by Biotechnology Value Fund L.P.$3.4M
Shares beneficially owned by Biotechnology Value Fund II L.P.$769K
Shares underlying pre-funded warrants held by Reporting Persons (aggregate)$6.4M
Reporting person / beneficial ownerBiotechnology Value Fund, L.P.
General partner of bvfBVF I GP LLC
Reporting person / beneficial ownerBiotechnology Value Fund II, L.P.
General partner of bvf2BVF II GP LLC
Reporting person / beneficial ownerBiotechnology Value Trading Fund OS LP
General partner of trading fund osBVF Partners OS Ltd.
Sole member of bvf gp and bvf2 gpBVF GP Holdings LLC
Investment manager of bvf, bvf2, and trading fund osBVF Partners L.P.
General partner of bvf partners l.p.BVF Inc.
IssuerTenax Therapeutics, Inc.
Director and officer of bvf inc.Mark N. Lampert

How TENX stock reacted

Close before

$1.62

Nov 13, 2026

First close after

-8.64%

$1.48

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for TENX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for TENX?

Click here

Frequently asked questions

What did TENX file with the SEC on Nov 16, 2026?

TENX filed a SCHEDULE 13G/A (SEC filing). Biotechnology Value Fund L.P. and affiliated entities filed an amended Schedule 13G disclosing beneficial ownership of approximately 9.99% of Tenax Therapeutics' common stock, including shares underlying pre-funded warrants subject to a 9.99% ownership blocker.

How do I read a SCHEDULE 13G/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).

How did TENX stock react to this filing?

TENX closed at $1.62 before the filing and $1.48 on Nov 16, 2026 (-8.64%).

Other TENX SEC filings

Get alerts when TENX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days